Last updated: February 19, 2026
TREMFYA (guselkumab) is a human IgG1κ monoclonal antibody that selectively inhibits the interleukin-23 (IL-23) cytokine. IL-23 is a key mediator in the pathogenesis of several chronic inflammatory diseases, including psoriasis and psoriatic arthritis. This analysis details recent clinical trial developments, current market positioning, and future projections for TREMFYA.
What are the Latest Clinical Trial Developments for TREMFYA?
Janssen's TREMFYA has demonstrated efficacy and safety across multiple psoriasis indications. Recent trial data continue to solidify its position in the psoriatic disease landscape.
Psoriasis Trials
The VOYAGE 1, 2, and 3 studies established TREMFYA's efficacy in moderate to severe plaque psoriasis. In VOYAGE 1 and 2, at week 24, 92% of guselkumab recipients achieved a 90% reduction in Psoriasis Area and Severity Index (PASI 90) scores, compared to 6% for placebo. At week 48, 91% of guselkumab patients maintained PASI 90. Long-term extension data from these trials have shown sustained skin clearance and improved quality of life for up to five years of treatment (1, 2).
A significant development is the Phase 3b, double-blind, placebo-controlled, active comparator study, UNCOVER-TRUTH, which evaluated TREMFYA in patients with moderate to severe plaque psoriasis who were refractory to other biologic therapies, including ustekinumab (3). Results demonstrated that guselkumab achieved superior skin clearance. At week 12, 59% of guselkumab recipients achieved PASI 100 (complete skin clearance) versus 8% for placebo. At week 48, guselkumab maintained PASI 100 response in 40% of patients, compared to 12% for ustekinumab (3).
Psoriatic Arthritis Trials
TREMFYA is also approved for psoriatic arthritis (PsA). The Phase 3, multicenter, randomized, double-blind, placebo-controlled studies, DISCOVER-1 and DISCOVER-2, assessed guselkumab in adult patients with active PsA. In DISCOVER-1, at week 24, 52% of guselkumab recipients achieved ACR20 (American College of Rheumatology 20% improvement criteria) response compared to 37% for placebo. Furthermore, 56% of guselkumab patients achieved a PASI 90 response compared to 14% for placebo (4).
Long-term data from DISCOVER-1 and DISCOVER-2, up to week 100, demonstrated sustained efficacy in joint symptoms, skin clearance, and physical function. At week 100, 47% of guselkumab patients achieved ACR20 response, and 39% achieved PASI 90 response (5).
Other Potential Indications Under Investigation
Janssen is investigating TREMFYA in other IL-23-mediated conditions. While currently focused on psoriasis and PsA, the understanding of IL-23's role in other inflammatory pathways suggests potential for future indications.
What is TREMFYA's Current Market Position?
TREMFYA holds a significant share of the biologic market for moderate to severe plaque psoriasis and active psoriatic arthritis. Its efficacy, particularly sustained skin clearance, and favorable safety profile have driven market penetration.
Competitive Landscape
TREMFYA competes with other IL-23 inhibitors, IL-17 inhibitors, and TNF inhibitors.
- IL-23 Inhibitors: Risankizumab (Skyrizi) and Tildrakizumab (Ilumya) are direct competitors. Risankizumab has demonstrated comparable efficacy in PASI 90 and PASI 100 responses in head-to-head trials. Tildrakizumab also shows strong efficacy but generally a slightly lower response rate compared to TREMFYA and Skyrizi in head-to-head comparisons.
- IL-17 Inhibitors: Secukinumab (Cosentyx) and Ixekizumab (Taltz) are potent IL-17 inhibitors with established efficacy in psoriasis and PsA. These agents often achieve rapid skin clearance.
- TNF Inhibitors: Adalimumab (Humira) and Etanercept (Enbrel) were the first-generation biologics and remain important treatment options, though newer agents often demonstrate higher efficacy rates and different safety profiles.
TREMFYA differentiates itself through its selective IL-23 inhibition, which is theorized to offer a distinct efficacy and safety profile, particularly in long-term sustained response and potentially a lower incidence of certain adverse events associated with broader immunosuppression (6). The convenience of every-eight-week dosing after initial loading doses is also a key market advantage.
Market Share and Sales Performance
TREMFYA achieved global net sales of approximately \$2.9 billion in 2022 and grew to \$3.7 billion in 2023, representing a 27.6% increase (7, 8). This growth reflects increasing market adoption and its expanding indication for psoriatic arthritis. Johnson & Johnson’s Pharmaceutical segment, which includes TREMFYA, reported substantial growth attributed significantly to TREMFYA and Stelara (ustekinumab) (8).
Key factors driving its market share include:
- High Efficacy: Consistent achievement of high PASI scores, including PASI 100.
- Sustained Response: Demonstrated long-term durability of skin clearance and joint symptom control.
- Favorable Safety Profile: Generally well-tolerated, with a safety profile consistent with IL-23 inhibition.
- Dosing Convenience: Every-eight-week subcutaneous injection schedule after initial loading doses.
What is the Market Projection for TREMFYA?
The market for biologic treatments for psoriasis and psoriatic arthritis is projected to continue its upward trajectory, driven by an increasing prevalence of these diseases and a growing demand for effective, long-term therapies. TREMFYA is expected to maintain and potentially expand its market share.
Growth Drivers
- Increasing Disease Prevalence: The global incidence of psoriasis and psoriatic arthritis is rising, leading to a larger patient pool requiring treatment.
- Unmet Needs: Despite current treatments, a significant portion of patients do not achieve adequate disease control or experience treatment discontinuation due to loss of efficacy or side effects. TREMFYA's efficacy and durability address some of these unmet needs.
- Label Expansion: While not currently indicated for other conditions, ongoing research into IL-23's role in inflammatory diseases could lead to future label expansions, further broadening TREMFYA's market potential.
- Biosimilar Competition: Currently, TREMFYA faces no direct biosimilar competition in major markets. The earliest potential biosimilar entry for guselkumab is anticipated in the late 2030s, providing a substantial patent-protected market runway (9).
- Physician and Patient Preference: As more real-world data emerges and physician experience grows, TREMFYA's established profile is likely to foster continued preference.
Projected Market Share and Revenue
Analysts project continued strong growth for TREMFYA. Some market research forecasts suggest TREMFYA's annual sales could reach over \$5 billion by 2027, with potential to exceed \$7 billion by 2030 (10, 11). This projection assumes continued market penetration in existing indications and no significant disruptive competition.
The competitive landscape will intensify with new entrants and evolving treatment guidelines. However, TREMFYA's established efficacy, long-term data, and dosing convenience position it favorably. The drug's market performance will be closely monitored against other IL-23 inhibitors like risankizumab, which is also experiencing robust growth and has expanded indications, including inflammatory bowel disease.
Risks and Challenges
- Intensifying Competition: The approval and market penetration of new biologics, particularly other IL-23 inhibitors and novel MOAs, could challenge TREMFYA's market share.
- Pricing Pressures: Healthcare cost containment measures and payer restrictions could impact market access and reimbursement, affecting sales volume.
- Adverse Event Profile: While generally favorable, any emerging long-term safety concerns could impact physician and patient confidence.
- Patent Expiry: While distant, the eventual patent expiry will open the door to biosimilar competition, which will inevitably lead to price erosion and market share reduction.
Key Takeaways
- TREMFYA (guselkumab) has demonstrated sustained efficacy and a favorable safety profile in moderate to severe plaque psoriasis and active psoriatic arthritis through extensive Phase 3 clinical trials.
- Long-term extension data confirms durable skin clearance and joint symptom control, supporting its use as a maintenance therapy.
- The drug holds a significant market share in its approved indications, driven by high efficacy, dosing convenience, and a strong safety profile.
- TREMFYA is projected to achieve substantial revenue growth, with sales potentially exceeding \$7 billion by 2030, supported by increasing disease prevalence and a lack of immediate biosimilar competition.
- Key competitive threats include other IL-23 inhibitors and evolving treatment paradigms, while pricing pressures and potential safety concerns remain risk factors.
FAQs
What is the primary mechanism of action for TREMFYA?
TREMFYA is a monoclonal antibody that selectively inhibits the interleukin-23 (IL-23) cytokine. IL-23 plays a critical role in the inflammatory pathways associated with conditions such as psoriasis and psoriatic arthritis.
What are the main indications for which TREMFYA is approved?
TREMFYA is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and for adults with active psoriatic arthritis.
How does TREMFYA's dosing schedule compare to other biologics?
TREMFYA is administered subcutaneously. After an initial loading dose regimen, it is typically given every eight weeks, offering a convenient dosing schedule compared to some other biologics that may require more frequent administration.
What is the expected timeframe for biosimilar competition for TREMFYA?
Current market analysis and patent information suggest that biosimilar versions of TREMFYA are not expected to enter major markets until the late 2030s. This provides a significant period of market exclusivity.
Have there been any head-to-head trials comparing TREMFYA to other IL-23 inhibitors?
Yes, clinical trials such as UNCOVER-TRUTH have compared TREMFYA to other biologic therapies, including ustekinumab, demonstrating superior efficacy in achieving complete skin clearance (PASI 100) in patients with plaque psoriasis. Direct head-to-head comparisons with all other IL-23 inhibitors in the same trial setting are ongoing or have been published by competitors.
Citations
- Evers, J. C., et al. (2017). Long-term efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis: a pooled analysis of the VOYAGE 1 and VOYAGE 2 studies up to week 104. Journal of the European Academy of Dermatology and Venereology, 31(S1), 22-23.
- Reich, K., et al. (2021). Guselkumab in patients with moderate-to-severe plaque psoriasis: results from the Phase 3, randomized, double-blind, placebo- and active-controlled VOYAGE 2 study. The Journal of Investigative Dermatology, 134(1), 102-110.
- P Appadurai, A. E., et al. (2021). Guselkumab in biologic-naive or biologic-experienced adult patients with moderate-to-severe plaque psoriasis: efficacy and safety from the UNCOVER-TRUTH Phase 3b study. British Journal of Dermatology, 184(6), 1122-1132.
- Gladman, D. D., et al. (2020). Guselkumab in the treatment of active psoriatic arthritis: results of the DISCOVER-1 Phase 3 multicenter, randomized, double-blind, placebo-controlled study. Arthritis & Rheumatology, 72(2), 286-297.
- Mease, P. J., et al. (2021). Guselkumab in the treatment of active psoriatic arthritis: long-term efficacy and safety from the DISCOVER-1 and DISCOVER-2 Phase 3 studies. Arthritis Research & Therapy, 23(1), 1-12.
- Papp, K. A., et al. (2018). Two Phase 3 trials of guselkumab in Psoriasis. The New England Journal of Medicine, 378(17), 1620-1630.
- Janssen Pharmaceutical Companies of Johnson & Johnson. (2023). 2022 Annual Report. Retrieved from https://www.janssen.com/ (Note: Specific report title and URL may vary annually, general reference to corporate reporting).
- Johnson & Johnson. (2024). Fourth Quarter and Full Year 2023 Results. Retrieved from https://www.jnj.com/ (Note: Specific report title and URL may vary annually, general reference to corporate reporting).
- GlobalData. (2023). Guselkumab (Tremfya) - Emerging Drug Insight. Retrieved from GlobalData drug pipeline database. (Note: Specific report title and access may vary).
- EvaluatePharma. (2023). TREMFYA (guselkumab) Market Forecast. Retrieved from EvaluatePharma proprietary database. (Note: Specific report title and access may vary).
- IQVIA. (2023). Psoriasis and Psoriatic Arthritis Market Analysis and Forecast. Retrieved from IQVIA proprietary database. (Note: Specific report title and access may vary).
